ZFGN Zafgen Inc.

0.83
-0.01  -2%
Previous Close 0.85
Open 0.85
Price To Book 0.43
Market Cap 31,174,305
Shares 37,370,301
Volume 139,543
Short Ratio
Av. Daily Volume 395,287

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from in vivo animal model to resolve current clinical hold due by the end of 2019 (not Phase 1).
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity

Latest News

  1. Zafgen Reports Second Quarter 2019 Operating and Financial Results
  2. Zafgen to Present at the Wedbush PacGrow Healthcare Conference
  3. Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061
  4. How Many Zafgen, Inc. (NASDAQ:ZFGN) Shares Do Institutions Own?
  5. Is Zafgen Inc (ZFGN) A Good Stock To Buy?
  6. Zafgen to Present at the JMP Securities Life Sciences Conference
  7. Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
  8. Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know
  9. Zafgen Announces Regulatory Update on ZGN-1061
  10. Zafgen: 1Q Earnings Snapshot
  11. Zafgen Reports First Quarter 2019 Operating and Financial Results
  12. Zafgen to Announce First Quarter 2019 Financial Results
  13. Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  14. Edited Transcript of ZFGN earnings conference call or presentation 11-Mar-19 9:00pm GMT
  15. Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc.
  16. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors
  17. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zafgen, Inc. Investors
  18. What Do Investors Need To Know About Zafgen, Inc.’s (NASDAQ:ZFGN) Growth?